Take a look behind the scenes of a recent Future Microbiology review, entitled ‘An update on drug repurposing: Is it useful for tacking antimicrobial resistance?’ as we ask the authors about what challenges and limitations drug repurposing faces, in addition to why this strategy could be a promising alternative to the traditional drug discovery pipeline.
Browsing: Drug Development
Xenleta™ (lefamulin), developed by Nabriva Therapeutics, has been approved by the US FDA for adults with community-acquired bacterial pneumonia, marking the first new antibiotic with a novel mechanism of action to be approved in nearly two decades.
The US FDA has approved Pretomanid tablets in combination with bedaquiline and linezolid for the treatment of specific types of drug-resistant pulmonary tuberculosis.
A study of four Ebola therapeutics demonstrated that two drugs showed significantly improved survival rates, leading to the trial being halted early.
Coagulation factors, which normally function to clot blood, have been demonstrated to have antibacterial action against Gram-negative bacteria in vitro and in mouse models.
US FDA approves RECARBRIO™ for complicated UTIs and complicated intra-abdominal infections: July’s industry headlines
Take a look at this month’s industry headlines including a US FDA approval for RECARBRIO™, positive results for XOFLUZA in children and new ACIP recommendations.
An in vitro study has identified potent antibiotic properties possessed by cannabidiol, discovering activity against Gram-positive bacteria such as Staphylococcus aureus and Streptococcus pneumoniae.
Take a look at this month’s industry headlines including US FDA approvals for Mavyret (hepatitis C) and Dengvaxia, a rejection for Contepo and profits for Gilead Sciences.
ECCMID19: Suvratoxumab completes Phase II for treatment of Staphylococcus aureus in the New Drugs 4 Bad Bugs program
Collaborative research efforts have seen a novel monoclonal antibody, suvratoxumab, complete a Phase II trial targeted towards Staphylococcus aureus. This SAATELLITE study comes as the first clinical trial in the Innovative Medicines Initiative, formed to develop alternative medicines to combat antibiotic resistance.
A single, oral dose of antimalarial DSM265 has cleared seven volunteers of a Plasmodium falciparum infection, according to the trial from the Medicines for Malaria Venture.